SLAMF7 and plasma cell myeloma: This inducible CAR-T design relies on an autocleavable receptor construct (synNotch)61 that activates CD24-targeted CAR expression upon recognition of MM specific makers (e.g. CD38, SLAMF7) on the surface of myeloma cells.